solo per uso di ricerca
N. Cat.: S3604
Struttura chimica
| Target correlati | NF-κB HDAC Antioxidant ROS IκB/IKK Nrf2 AP-1 MALT NOD |
|---|---|
| Altro ADC Cytotoxin Inibitori | SN-38 Luteolin (+)-Bicuculline Rutin Artemisinin BHQ Pinocembrin Luteoloside Lappaconite HBr Gramine |
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dell'attività | PMID |
|---|---|---|---|---|---|---|
| HT-29 | Cytotoxicity against | Cytotoxicity against human HT-29 cells, IC50=0.0021μM | 21470864 | |||
| HCT116 | Cytotoxicity against | Cytotoxicity against human HCT116 cells assessed as decrease in cell viability, IC50=0.0047μM | 31121546 | |||
| SKOV3 | Antiproliferative activity against | 72 hrs | Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay, IC50=0.006μM | 20833543 | ||
| SKOV3 | Cytotoxicity against | 72 hrs | Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay, IC50=0.006μM | 24378709 | ||
| SKOV3 | Cytotoxic activity against | 72 hrs | Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0072μM | 28011223 | ||
| KBM5 | Cytotoxicity against | 72 hrs | Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay, IC50=0.0083μM | 20149665 | ||
| SKOV3 | Cytotoxicity against | Cytotoxicity against human SKOV3 cells by SRB assay, IC50=0.009μM | 19637874 | |||
| MDA-MB-468 | Cytotoxicity against | Cytotoxicity against human MDA-MB-468 cells by SRB assay, IC50=0.01μM | 19637874 | |||
| HCT116 | Cytotoxicity against | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50=0.01μM | 19637874 | ||
| SKOV3 | Cytotoxicity against | 72 hrs | Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay, IC50=0.01μM | 19637874 | ||
| KBM5 | Cytotoxicity against | 72 hrs | Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay, IC50=0.0103μM | 20149665 | ||
| Rh30 | Cytotoxicity against | 72 hrs | Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay, IC50=0.014μM | 19637874 | ||
| A549 | Antagonist activity at | Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay, IC50=0.014μM | 23895492 | |||
| SGC7901 | Cytotoxicity against | 72 hrs | Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay, IC50=0.015μM | 19637874 | ||
| MOLT4 | Cytotoxicity against | 72 hrs | Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay, IC50=0.017μM | 19637874 | ||
| A549 | Cytotoxic activity against | 72 hrs | Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0175μM | 28011223 | ||
| SMMC7721 | Cytotoxicity against | 72 hrs | Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay, IC50=0.018μM | 19637874 | ||
| PC3 | Cytotoxic activity against | 72 hrs | Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0183μM | 28011223 | ||
| MCF7 | Cytotoxicity against | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50=0.019μM | 19637874 | ||
| A549 | Cytotoxicity against | Cytotoxicity against human A549 cells, IC50=0.019μM | 21470864 | |||
| PC3 | Cytotoxicity against | Cytotoxicity against human PC3 cells by SRB assay, IC50=0.02μM | 19637874 | |||
| Bel7402 | Cytotoxicity against | 72 hrs | Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay, IC50=0.02μM | 19637874 | ||
| PC3 | Antiproliferative activity against | 72 hrs | Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay, IC50=0.02μM | 20833543 | ||
| PC3 | Cytotoxicity against | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay, IC50=0.02μM | 24378709 | ||
| PC3 | Cytotoxicity against | Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay, IC50=0.02μM | 25467158 | |||
| 786-O | Cytotoxicity against | 72 hrs | Cytotoxicity against human 786-O cells after 72 hrs by MTT assay, IC50=0.022μM | 19637874 | ||
| A549 | Antagonist activity at | Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA, IC50=0.023μM | 23895492 | |||
| MDA-MB-231 | Cytotoxicity against | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50=0.024μM | 19637874 | ||
| DU145 | Cytotoxicity against | 72 hrs | Cytotoxicity against human DU145 cells after 72 hrs by MTT assay, IC50=0.024μM | 19637874 | ||
| HO8910 | Cytotoxicity against | 72 hrs | Cytotoxicity against human HO8910 cells after 72 hrs by MTT assay, IC50=0.028μM | 19637874 | ||
| HCT15 | Cytotoxicity against | 72 hrs | Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay, IC50=0.029μM | 19637874 | ||
| A549 | Growth inhibition of human | Growth inhibition of human A549 cells, IC50=0.03μM | 28814374 | |||
| 32D | Cytotoxicity against | 72 hrs | Cytotoxicity against mouse 32D cells harboring wild type Bcr-Abl after 72 hrs by MTS assay, IC50=0.032μM | 20149665 | ||
| U251 | Cytotoxicity against | Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay, IC50=0.033μM | 25467158 | |||
| 32D | Cytotoxicity against | 72 hrs | Cytotoxicity against imatinib-resistant mouse 32D cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay, IC50=0.034μM | 20149665 | ||
| PC3 | Cytotoxicity against | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by MTT assay, IC50=0.043μM | 19637874 | ||
| KB | Cytotoxicity against | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by MTT assay, IC50=0.043μM | 19637874 | ||
| HepG2 | Cytotoxicity against | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay, IC50=0.0433μM | 30613335 | ||
| HeLa | Cytotoxicity against | 72 hrs | Cytotoxicity against human HeLa cells after 72 hrs by MTT assay, IC50=0.047μM | 19637874 | ||
| U251 | Cytotoxicity against | 72 hrs | Cytotoxicity against human U251 cells after 72 hrs by MTT assay, IC50=0.049μM | 19637874 | ||
| K562 | Cytotoxicity against | 72 hrs | Cytotoxicity against human K562 cells after 72 hrs by MTT assay, IC50=0.05μM | 19637874 | ||
| NIH/3T3 | Cytotoxicity against | Cytotoxicity against mouse NIH/3T3 cells assessed as decrease in cell viability, IC50=0.05μM | 31121546 | |||
| SW1116 | Cytotoxicity against | 72 hrs | Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay, IC50=0.052μM | 19637874 | ||
| A549 | Cytotoxicity against | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50=0.059μM | 19637874 | ||
| HeLa | Cytotoxicity against | Cytotoxicity against human HeLa cells assessed as decrease in cell viability, IC50=0.087μM | 31121546 | |||
| Jurkat | Cytotoxicity against | Cytotoxicity against human Jurkat cells assessed as decrease in cell viability, IC50=0.14μM | 31121546 | |||
| MKN28 | Cytotoxicity against | 72 hrs | Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay, IC50=0.2μM | 19637874 | ||
| MDCK | Cytotoxicity against | Cytotoxicity against MDCK cells assessed as decrease in cell viability, IC50=1.2μM | 31121546 | |||
| Pkd1-/- | Induction of | Induction of cell growth arrest in mouse Pkd1-/- cells in presence of calcium | 17360534 | |||
| Pkd1-/- | Increase in | 100 nM | 96 hrs | Increase in p21CIP/WAF expression in mouse Pkd1-/- cells at 100 nM after 96 hrs by Western blot analysis | 17360534 | |
| Pkd1+/- | Increase in | 100 nM | Increase in PC2 dependent calcium release in mouse Pkd1+/- cells at 100 nM | 17360534 | ||
| Pkd1-/- | Increase in | 100 nM | Increase in PC2 dependent calcium release in mouse Pkd1-/- cells at 100 nM | 17360534 | ||
| Pkd1-/- | Increase in | 50 uM | Increase in calcium release in mouse Pkd1-/- cells at 50 uM in presence of RyR antagonist dantrolene | 17360534 | ||
| Pkd2+/- | Growth inhibition of PC2 expressing mouse | 100 nM | 24 hrs | Growth inhibition of PC2 expressing mouse Pkd2+/- cells as cell death at 100 nM after 24 hrs | 17360534 | |
| KBM5 | Cytotoxicity against | 0.001 to 17 uM | 72 hrs | Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl at 0.001 to 17 uM after 72 hrs by MTS assay | 20149665 | |
| KBM5 | Cytotoxicity against | 0.001 to 17 uM | 72 hrs | Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant at 0.001 to 17 uM after 72 hrs by MTS assay | 20149665 | |
| LNCAP | Antagonist activity at | 5 uM | 24 hrs | Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay | 27994731 | |
| LNCAP | Antagonist activity at | 500 nM | 24 hrs | Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 500 nM after 24 hrs by dual luciferase reporter gene assay | 27994731 | |
| HepG2 | Antitumor activity against | 0.2 mg/kg | 15 days | Antitumor activity against human HepG2 cells xenografted in Balb/c nude mouse assessed as reduction in tumor growth at 0.2 mg/kg, ip administered once daily for 15 days | 30613335 | |
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 360.4 | Formula | C20H24O6 |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 38748-32-2 | Scarica SDF | Conservazione delle soluzioni stock |
|
|
|
In vitro |
DMSO
: 72 mg/mL
(199.77 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.
| Targets/IC50/Ki |
NF-κB
HSF1
MDM2
|
|---|---|
| In vitro |
Triptolide is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. This compound is shown to inhibit the expression of IL-2 in activated T cells at the level of purine-box/nuclear factor and NF-κB mediated transcription activation. It inhibits the proliferation and colony formation of tumor cells at extremely low concentrations (2–10 ng/mL). This chemical has an inhibitory activity on breast, stomach and leukemia cell line HL-60 cells. It induces apoptosis in tumor cells by blocking NF-κB activation and sensitizing tumor cells for TNF-&alpha induced programmed cell death.
|
| In vivo |
Triptolide synergizes with cyclosporin A in promoting graft survival in animal models and in suppression of graft versus host disease in allogeneic bone marrow transplants. In addition, it induces apoptosis in tumor cells and potentiates tumor necrosis factor (TNF-α) induction of apoptosis in part through the suppression of c-IAP2 and c-IAP1 induction. This compound treatment for 2–3 weeks inhibits the growth of xenografts formed by four different tumor cell lines (B16 melanoma, MDA-435 breast cancer, TSU bladder cancer, and MGC80-3 gastric carcinoma), indicating that TPL has a broad spectrum of activity against tumors that contain both wild-type and mutant forms of p53. In addition, it inhibits experimental metastasis of B16F10 cells to the lungs and spleens of mice. It has in vitro and in vivo activities against mouse models of polycystic kidney disease. LD50: Mice 0.83mg/kg (i.v.).
|
Riferimenti |
|
| Metodi | Biomarcatori | Immagini | PMID |
|---|---|---|---|
| Western blot | c-Jun MDM2 p-AKT / AKT / p-Foxo3a / Foxo3a / p53 p-PI3K / PI3K / p85 / p110 |
|
22666381 |
| Growth inhibition assay | Cell viability |
|
22666381 |
(dati da https://clinicaltrials.gov, aggiornato il 2026-03-05)
| Numero NCT | Reclutamento | Condizioni | Sponsor/Collaboratori | Data di inizio | Fasi |
|---|---|---|---|---|---|
| NCT05166616 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma |
City of Hope Medical Center |
2022-03-07 | PHASE1 |
| NCT03403569 | COMPLETED | HIV-infection/AIDS |
Peking Union Medical College Hospital |
2018-09-01 | PHASE3 |
| NCT02219672 | UNKNOWN | AIDS/HIV PROBLEM |
Peking Union Medical College |
2014-07 | PHASE3 |
| NCT02115659 | UNKNOWN | Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Shanghai Changzheng Hospital |
2014-04 | PHASE3 |
| NCT01817283 | UNKNOWN | HIV |
LI Taisheng |
2013-01 | PHASE1; PHASE2 |
| NCT00801268 | TERMINATED | Polycystic Kidney |
Zhi-Hong Liu, M.D. |
2008-11 |